POSTS ABOUT SCIENTIFIC NOTES

Chimeras: multi-epitope bio-markers

Figure 1.Chimeras bio-markers

At Rekom Biotech we have specialized in the design and production of next-generation bio-markers: chimeras or multi-epitope bio-markers, which have improved their antigenic properties such as sensitivity and specificity.

EPITOPE ANALYSIS

SEQUENCE ANALYSIS

3D STUDIES

Rekom Biotech chimeras bio-markers

Written by Ana Camacho.

Biotinylated bio-markers

Figure 1.Biotinylated Bio-marker

In many ways, a conjugated bio-marker can be the solution to different problems arisen in a new IVD test development. A common problem caused by most of the surfaces is protein denaturation due to the relatively high surface by hydrophobicity. Additionally, there may be larger steric influence on binding events due to the close proximity of the surface and the sensor molecules. The specific orientation may also improve the stability of attached proteins and increase the sensitivity of the assay by exposure of its antigenic regions.

Conventional conjugation methods generally work well with antibodies; however, results with many antigens of less well-established structures are less constant. This is probably the main reason why double-antigen sandwich ELISAs (DAS-ELISA) are not as commonly used for antibody detection as indirect ELISA.

To circumvent the effect on antigenic structure caused by conventional chemical conjugation that could result in decrease in sensitivity of DAS-ELISAs, Rekom Biotech has developed a product line of biotinylated antigens, offering to our customers the possibility to buy their favourite antigen but conjugated in its C-terminus. This molecule allows the specific interaction of the biotinylated antigens to the streptavidin protein.

Why biotinylated?

The extremely specific and high affinity binding of biotin by avidin and/or streptavidin (K_d ≈ 10^-14M) results in specific detection systems of very high sensitivity. A clear advantage of this system is that with a common strep-HRP, we can obtain conjugated complex of all our references without the necessity of performing the peroxidation of each reference.

The biotin is fused to a linker which maintains the molecule away to the antigen surface, avoiding steric hindrance between the biotin and the antigenic regions involved in Ab-binding. Thus, the Ab interaction will not be compromised with the conjugation.

Figure 2. Interaction between an antigen (green) vs Fab region of an Ab (pink). In red are specified the amino acids that usually are used in conjugation procedures. Some of these amino acids are part of the epitope region of the antigen. The conjugation would interfere with the Ab-binding, decreasing the antigenic capacity of the bio-marker.

As there is just one biotin per protein molecule, our conjugated bio-markers will show a higher inter-lot reproducibility and this will facilitate the reproducibility of our customers´ IVD test also.

Biotinylated applications

1. Antigen orientation in streptavidin-coated plates.
   
   
   
   
2. Detection in IgM capture assays.
   
   
   
   
3. Detection in DAS assays.
   
   
   
   
4. Bonding to gold and other nanoparticles coated with streptavidin.
   
   
   
   

Rekom Biotech biotinylated bio-markers

Written by Ana Camacho.

Design at the service of science

Human cytomegalovirus (HCMV) is endemic to populations throughout the world, and 50-80% of the adults in developed nations are sero-positive for this virus. Commercial ELISAs for detecting IgG are very sensitive and specific. Nevertheless, there are several problems regarding IgM detection. One of the difficulties that the diagnostic laboratory has faced over the past 10 years is the lack of agreement between commercial tests for the detection of CMV-specific IgM. This lack of agreement has its roots in the different viral preparations used to detect IgM antibodies to CMV. Rekom Biotech has performed the design of a new CMV recombinant polyepitope chimeric antigen (RAG0109), composed by different sensitive and specific antigenic determinants from some CMV proteins. This recombinant polyepitope chimeric antigen was tested in parallel with other CMV bio-markers such as the Rekom Biotech CMV recombinant proteins pp150 (RAG0091) and pp52 (RAG0090) and pp65 (RAG0016). The in house indirect IgM ELISA assay was carried out by using a battery of pre-validated sera with the commercial ELISA capture IgM test from Vidas:

Figure 1: Indirect IgM ELISA assay. Proteins were coating the plates at a final concentration of 1 µg/ml. All these experiments used anti-IgG as sorbent and anti-IgM-HRP. Sera were used in a 1:100 dilution. P means pre-validated sera by the Vidas test as positive; N means pre-validated sera by the Vidas test as negative.

These preliminary experiments suggest that the recombinant polyepitope chimeric antigen designed and produced by Rekom Biotech, RAG0109, recovers some pre-validated IgM positive sera which are not initially detected by two of the best antigens described in bibliography for CMV diagnosis: pp52 and pp150, showing the presence in merely one antigen of some important epitopes for this specific diagnostic.

To find more interesting information on regards recombinant antigen RAG0109, please click here.

Written by Ana Camacho.

Rekom Biotech issues a white paper on antigens titration

Recently, ReKom Biotech has published a white paper concerning good practices for antigen titration. This may be seen as an old issue. However, from the point of view of a data analyst the approaches in the literature are not really convincing. Titration experiments should be designed to obtain the most information on how to use the antigen at the lowest cost, that is, with the lowest number of experiments. It should be noted that, while the antigen may be used for quantitative or qualitative analysis, the titration experiments should be designed differently in both cases. The published paper is focused on qualitative analysis since the main goal of the titration experiments in ReKom Biotech is to convince our customers of the high quality of our products. We have devoted considerable efforts to develop titration procedures to indicate the customers at which concentration the antigen best discriminates between positive and negative serum of a given disease. Existent and widely used procedures present several drawbacks. For instance, in most standard titration experiments, such as in Chequerboard Titration (CBT), one single positive and negative sera are employed. From a statistical point of view, this is not a good approach since results are very dependent on the specific sera chosen. On the other hand, when several positive and negative sera are included in the experiment, the results are not assessed with the adequate tools. For instance, we could not find a single paper which compared the outcomes of positive and negative sera with a simple test of significance. The white paper we have published is intended to show clients that we use well-grounded methods to measure the quality of our products, and also to give details on these methods.

"Tritation Experiments"

Written by Jose Camacho Páez.